by The Ebola virus causes severe hemorrhagic fever in humans and nonhuman primates with high fatality rates. The first Ebola virus was discovered in 1976 near the Ebola River in the Democratic Republic of Congo. Since then, several outbreaks have occurred intermittently, primarily in Central and West Africa. The key symptoms of Ebola include fever, headache, joint and muscle aches, sore throat, and weakness, followed by diarrhea, vomiting, and stomach pain. Severe cases of Ebola infection are characterized by bleeding inside and outside of the body. With no proven treatment options available, prevention through vaccinations is the most effective approach to control Ebola outbreaks.
The global Ebola Vaccine Market is estimated to be valued at US$ 5.83 Bn in 2023 and is expected to exhibit a CAGR of 14% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends
One of the major trends in the Ebola vaccine market is the development of combination vaccines. Combination vaccines aim to protect individuals from multiple diseases through fewer injections. For instance, Johnson & Johnson is developing an Ebola/Marburg viral hemorrhagic fever combination vaccine candidate named Ad26/MVA-BN-Filo. Similarly, Merck & Co. Inc. is developing a VSV-ZEBOV (Ervebo)/Lassa fever virus vaccine candidate. Such combination vaccines are expected to boost market growth over the forecast period. Additionally, research focusing on improving the immunogenicity and safety profile of Ebola vaccines through novel vaccine platforms such as self-amplifying mRNA vaccines is anticipated to provide lucrative opportunities in the market in the coming years.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is low due to high R&D costs involved in developing effective Ebola vaccines.Stringent regulatory approvals and specialized distribution channels also limit new companies from entering this market.
Bargaining power of buyers: The bargaining power of buyers is moderate as healthcare facilities and governments are the major buyers of Ebola vaccines. Buyers can negotiate on pricing and contracts.
Bargaining power of suppliers: A few players control the supply of raw materials and key components required for manufacturing Ebola vaccines. This gives suppliers a moderate bargaining power.
Threat of new substitutes: There are no effective substitutes for Ebola vaccines currently. Development of new alternative treatment options can pose a threat in the long run.
Competitive rivalry: The Ebola vaccine market witnesses stiff competition between existing players. Players compete based on vaccine efficacy, pricing, and market reach.
Key Takeaways
The global Ebola Vaccine Market Size is expected to witness high growth. Regional analysis showed that North America currently dominates the market due to frequent outbreaks and mature healthcare infrastructure. Europe and Asia Pacific are the fastest growing markets for Ebola vaccines.
Regional analysis: North America is the largest market for Ebola vaccines currently owing to a supportive regulatory environment and mature healthcare system. Frequent outbreaks in the region also drive vaccine adoption. Europe is expected to witness fastest growth during the forecast period supported by research funding and vaccine stockpiling initiatives. Asia Pacific also provides lucrative opportunities for market players due to improving the healthcare sector and increasing awareness about Ebola.
Key players: Key players operating in the Ebola vaccine market are Siegfried, Sanofi, Johnson Matthey, Mallinckrodt, Noramco, Unichem Laboratories, Arevipharma GmbH, Resonance-labs, Sun Pharmaceutical Industries Ltd., Rusan Pharma, Micro Orgo Chem, and Faran Shimi Pharmaceutical Co. Sanofi’s VSV-ZEBOV is the only approved vaccine currently available globally.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
